Biotech News

Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access

Allogene Therapeutics (ALLO)Allogene TherapeuticsCompany update

Company to Host In-Person Event at ASH 2026 Featuring New Market Research and a Physician Panel Discussion on Barriers to CAR T Access, Community Adoption in Large B-Cell Lymphoma (LBCL), and the Potential Role of Cemacabtagene Ansegedleucel (Cema-cel) to Expand Patient Access New Market Research

Related news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

Stock data

Close
0.67 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States